People: Phosphagenics Limited (POH.AX)

POH.AX on Australia Stock Exchange

0.08AUD
10 Feb 2010
Price Change (% chg)

$0.01 (+11.59%)
Prev Close
$0.07
Open
$0.07
Day's High
$0.08
Day's Low
$0.07
Volume
1,279,359
Avg. Vol
5,104,103
52-wk High
$0.20
52-wk Low
$0.05

view people for:

Summary

Name Age Since Current Position
Vizard, Andrew 51 2000 Non-Executive Chairman of the Board, Independent Director
Rosen, Harry 61 2008 President, Chief Executive Officer, Managing Director, Executive Director
Hodges, Alister 2008 Chief Financial Officer
Ogru, Ersa 33 2009 Chief Operating Officer, Executive Director
Banti, Fred 2008 Senior Vice President, Chief Business Officer
Gavin, Paul 2009 Vice President - Research & Development
Garbutt, Mourice Company Secretary
West, S. Director - Vital Health Services Pty Ltd
McSwiggan, M. Investor Relations Manager
Addison, Jonathan 56 2002 Non-Executive Independent Director
Mills, John 68 2004 Non-Executive Independent Director
Ashton, Michael 63 2008 Non-Executive Independent Director
» Insider Trading

Biographies

Name Description
Vizard, Andrew Associate Professor Andrew Lancelot Vizard is Non-Executive Chairman of the Board, Independent Director of Phosphagenics Ltd. With a background in research and agricultural consultancy, Professor Vizard is the Senior Consultant with and former Director of the Mackinnon Project at the University of Melbourne. This enterprise is recognized as a leader in delivering practical advice to farmer and agribusiness on a wide range of agricultural and economic issues. Professor Vizard is the author of over fifty scientific papers. Professor Vizard has formally been a board member of numerous statutory, scientific and commercial organisations. He is currently a Non-Executive Director of Ridley Corporation Ltd and Animal Health Australia Ltd, a Trustee of the Australian Wool Education Trust and a member of the Management Advisory Committee for Melbourne Water. Professor Vizard is a member of the Company’s Audit, Compliance and Corporate Governance Committee.
Rosen, Harry Mr. Rosen is President, Chief Executive Officer, Managing Director, Executive Director of Phosphagenics Limited. He is a non-practicing lawyer. He is one of the founders of Betatene Limited and Denehurst Limited, two formerly ASX listed companies which commercialised significant research and development. Betatene is the world’s largest producer of natural beta carotene. After the purchase of Betatene Limited by Henkel Corporation, Mr Rosen served as Vice President, Corporate Development. As a Vice President of Henkel Corporation, he worked for a number of years in the USA in the nutrition and health care industries. Mr Rosen has consulted to many technology companies assisting them with the commercialisation of new technologies. He has had significant experience in the areas of seed capital raising, stock exchange listings, taxation and corporate law. Mr Rosen graduated from the Australian National University (B.A.-Psychology) in 1970 and Melbourne University (LLB) in 1973.
Hodges, Alister
Ogru, Ersa Dr. Esra Ogru is Chief Operating Officer, Executive Director of Phosphagenics Limited. Dr Ogru is responsible for the co-ordination and management of pre-clinical, clinical and development research and manufacturing in Australia and internationally. She achieves this through leadership of a team of experienced pharmaceutical scientists and chemists and strategic collaborations. In this role, Dr Ogru has developed commercial opportunities for both the Company’s nutraceutical division and pharmaceutical technologies, such as transdermal drug delivery and drug enhancement platforms for cancer, heart disease and chronic pain management. Dr Ogru has many years experience in both the academic and commercial aspects of the industry and has publications in peer-reviewed journals. Prior to joining Phosphagenics in 2001, Dr Ogru carried out significant research on obesity and diabetes. Additionally she has considerable experience in the management and coordination of pre-clinical and clinical development of pharmaceutical products.
Banti, Fred Fred Banti has been appointed as Senior Vice President and Chief Business Officer of Phosphagenics Limited. Mr. Banti has more than 27 years’ experience as a pharmaceutical executive with strong management credentials in corporate, business and strategy development, portfolio and project management, commercial assessments and research & development. From 2006 to 2008, Mr. Banti was VP Business Development for Gemin X Inc.; a private Venture backed Oncology Company. Prior to that, he was VP Life Sciences at Wood Mackenzie, VP Corporate Development for Penwest Pharmaceutical, VP Global Business Development for Novartis Oncology and Senior Director, Corporate Licensing and Global Head of Infectious Disease Licensing at Pharmacia.
Gavin, Paul Dr Paul Gavin has been appointed as Vice President - Research & Development of Phosphagenics Limited. Dr Gavin is now responsible for the global coordination and management of the Company’s pre-clinical and clinical research. Since joining the Company in 2002, Dr Gavin has developed opportunities in both the Company’s nutraceutical and pharmaceutical divisions such as transdermal drug delivery systems and drug enhancement platforms for chronic pain management. Prior to his joining Phosphagenics, Dr Gavin conducted research at Monash University’s Department of Biochemistry and Molecular Biology. Dr Gavin holds a Bachelor of Science (Hons) and a PhD in Biochemistry & Molecular Biology from Monash University, Melbourne. He is experienced in many aspects of academic and commercial research and development and has published in peer journals.
Garbutt, Mourice Mr Garbutt is Company Secretary of Phosphagenics ltd. Through his professional corporate secretarial and compliance service company, provides secretarial, clerical and corporate governance support to client companies in Australia many of which are listed on the ASX Limited. Mr Garbutt has substantial experience in the area of listed company secretarial matters, compliance and corporate governance with over 30 years experience primarily within Australia but having worked in the Pacific region and Europe.
West, S.
McSwiggan, M.
Addison, Jonathan Mr. Addison is Non-Executive Independent Director of Phosphagenics Limited. Mr Addison has over 30 years in the investment management industry, including wide experience in superannuation. Mr Addison has over 30 years in the investment management industry, including wide experience in superannuation. Currently he is the Investment Manager (formerly Fund Manager) of the Meat Industry Employee Superannuation Fund (“MIESF”) whom he joined in June 1999 and where he is responsible for the investment management of MIESF. Prior to his appointment to MIESF, Mr Addison was a Director and Asset Consultant within the Corporate Finance section of PricewaterhouseCoopers and in this role was responsible for establishing an investment consulting practice with clients ranging from superannuation funds to insurance funds and funds managers. Prior to that, he was Manager Investment Consultant at Sedgwick Noble Lowndes. Mr Addison also holds Non-Executive Directorships with Austcorp Group Limited , Austcorp Funds management Limited, African Enterprise Limited, African Enterprises New Zealand Limited, Hawksbridge Limited, Global Masters Fund Limited and TPCG Limited. Mr Addison is the Chairman of the Company’s Audit, Compliance and Corporate Governance Committee.
Mills, John Professor Mills is Non-Executive Independent Director of Phosphagenics Limited. Professor Mills has a long and distinguished career in medical research, clinical medicine and biomedical business. In addition to his position as a Non-Executive Director of Phosphagenics, he is Executive Chairman of Cavidi AB, Executive Director of TissuePath Pty Ltd, a Non-Executive Director of GBS Venture Partners Pty Ltd. He was previously a Non-Executive Director (1995-2003) and Chairman (2001-2) of AMRAD Corporation; a Non- Executive Director of Narhex Life Sciences Limited (2001-5) and Managing Director from 2005 to December 2007. He is also a Non-Executive Director of the Prostate Cancer Foundation of Australia and Chair of the PCFA Research Committee. He holds professional appointments at Monash University, the University of California, San Francisco and RMIT, and is a consulting physician at the Alfred and Austin Hospitals in Melbourne. Professor Mills has published over two hundred scientific articles and has served as a consultant to the pharmaceutical industry and governments, the World Health Organization and the United Nations. Professor Mills is a member of the Company’s Audit, Compliance and Corporate Governance Committee.
Ashton, Michael Michael Ashton is Non-Executive Independent Director of Phosphagenics Ltd. Mr Ashton has more than thirty years’ experience in the international pharmaceutical industry having held senior management positions with Merck Inc. and Pfizer Inc., and executive board positions with Faulding Inc. and SkyePharma Plc. Mr Ashton was CEO and Director of SkyePharma Plc., initially he was responsible for the re-organisation of SkyePharma AG as a public enterprise (1997 – 1998). In 1998 he took over responsibility of the operations of the SkyePharma Plc. group and re-organised the international structure in Europe and the U.S. and the world wide Business Development Group. Earlier Mr Ashton was Chairman, President and CEO of Faulding Inc., the U.S. subsidiary he opened for FH Faulding, Australia’s largest pharmaceutical company, and CEO of Purepac Inc. During that time, he supervised the start-up of David Bull in the U.S. and Canada and oversaw restructuring of Purepac Inc., into a leader of the U.S. generic pharmaceutical industry. In addition, Mr Ashton served with Pfizer International for fourteen years in various roles, which included Director of Pharmaceutical Business Development for Europe/Canada, Vice President of Pharmaceutical Development for Africa/Middle East, Pharmaceutical Business Director of Nigeria and Group Product Manager for the International Division in New York. Mr Ashton previously applied his pharmacist background to various management positions during six years at Merck Sharp and Dohme in Sydney and the U.S. Mr Ashton is a member of the Boards of Hikma Pharmaceuticals Plc, Proximagen Neuroscience Plc and Transition Therapeutics Inc. Mr Ashton holds a Bachelor of Pharmacy degree from Sydney University and a Masters in Business Administration from Rutger University, New Jersey, USA.

Basic Compensation

Name Fiscal Year Total
Vizard, Andrew 76,000
Rosen, Harry 302,159
Hodges, Alister 169,345
Ogru, Ersa 231,540
Banti, Fred 367,876
Gavin, Paul --
Garbutt, Mourice --
West, S. 100,000
McSwiggan, M. 99,077
Addison, Jonathan --
Mills, John --
Ashton, Michael --
As Of 30 Dec 2008

Insider Trading

» Full list on Insider Trading
view people for: